Journal of Clinical Oncology, Vol 19, Issue 6
(March), 2001: 1664-1670
© 2001 American Society for Clinical Oncology
Safety of the Synthetic Retinoid Fenretinide: Long-Term Results From a Controlled Clinical Trial for the Prevention of Contralateral Breast Cancer
By Tiziana Camerini,
Luigi Mariani,
Giuseppe De Palo,
Ettore Marubini,
Maria Gaetana Di Mauro,
Andrea Decensi,
Alberto Costa,
Umberto Veronesi
From the Istituto Nazionale Tumori and Istituto Europeo di Oncologia, Milan, Italy.
Address reprint requests to Giuseppe De Palo, MD, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy.
PURPOSE: To describe the pattern of occurrence of adverse events commonly arising during treatment with fenretinide, a synthetic retinoid under investigation for cancer prevention.
PATIENTS AND METHODS: The series includes 2,867 women accrued in a trial aimed at assessing the effect of fenretinide on the prevention of second breast malignancy. Women were randomly assigned to receive no treatment (1,435 patients) or 5-year fenretinide treatment (1,432 patients). In terms of disease recurrence in the breast, the trial showed a possible beneficial effect of the compound in premenopausal women, and an opposite trend in postmenopausal women. End points considered for safety assessment were the occurrence of diminished dark adaptation, dermatologic disorders, gastrointestinal symptoms, disorders of the ocular surface, and abnormal laboratory values.
RESULTS: The most common adverse events were diminished dark adaptation (cumulative incidence, 19.0%) and dermatologic disorders (18.6%). Less common events were gastrointestinal symptoms (13.0%) and disorders of the ocular surface (10.9%). In comparison, incidence figures in the control arm were 2.9% for diminished dark adaptation, 2.9% for dermatologic disorders, 5.4% for gastrointestinal symptoms, and 3.2% for disorders of the ocular surface. Symptoms occurring during fenretinide treatment tended to recover with time. No between-group difference was observed for the occurrence of laboratory data abnormalities. Overall, 63 (4.4%) treatment discontinuations were caused by adverse events.
CONCLUSION: Given the number of patients involved in the study and the prolonged intake of the drug, the experience on fenretinide tolerability can be considered sufficiently reassuring to justify further testing of the retinoid.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Decensi, C. Robertson, A. Guerrieri-Gonzaga, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, V. Galimberti, E. Cassano, et al.
Randomized Double-Blind 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in High-Risk Premenopausal Women
J. Clin. Oncol.,
August 10, 2009;
27(23):
3749 - 3756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Guilbault, G. Wojewodka, Z. Saeed, M. Hajduch, E. Matouk, J. B. De Sanctis, and D. Radzioch
Cystic Fibrosis Fatty Acid Imbalance Is Linked to Ceramide Deficiency and Corrected by Fenretinide
Am. J. Respir. Cell Mol. Biol.,
July 1, 2009;
41(1):
100 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Guilbault, J. B. De Sanctis, G. Wojewodka, Z. Saeed, C. Lachance, T. A. A. Skinner, R. M. Vilela, S. Kubow, L. C. Lands, M. Hajduch, et al.
Fenretinide Corrects Newly Found Ceramide Deficiency in Cystic Fibrosis
Am. J. Respir. Cell Mol. Biol.,
January 1, 2008;
38(1):
47 - 56.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Sabichi, S. P. Lerner, E. N. Atkinson, H. B. Grossman, N. P. Caraway, C. P. Dinney, D. F. Penson, S. Matin, A. Kamat, L. L. Pisters, et al.
Phase III Prevention Trial of Fenretinide in Patients with Resected Non Muscle-Invasive Bladder Cancer
Clin. Cancer Res.,
January 1, 2008;
14(1):
224 - 229.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Veronesi, L. Mariani, A. Decensi, F. Formelli, T. Camerini, R. Miceli, M. G. Di Mauro, A. Costa, E. Marubini, M. B. Sporn, et al.
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer
Ann. Onc.,
July 1, 2006;
17(7):
1065 - 1071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Zanardi, D Serrano, A Argusti, M Barile, M Puntoni, and A Decensi
Clinical trials with retinoids for breast cancer chemoprevention.
Endocr. Relat. Cancer,
March 1, 2006;
13(1):
51 - 68.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Lee, J. M. Skolnik, and P. C. Adamson
Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency
J. Clin. Oncol.,
November 20, 2005;
23(33):
8431 - 8441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Shishodia, A. M. Gutierrez, R. Lotan, and B. B. Aggarwal
N-(4-Hydroxyphenyl)Retinamide Inhibits Invasion, Suppresses Osteoclastogenesis, and Potentiates Apoptosis through Down-regulation of I{kappa}B{alpha} Kinase and Nuclear Factor-{kappa}B-Regulated Gene Products
Cancer Res.,
October 15, 2005;
65(20):
9555 - 9565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-M. Simeone, C.-X. Deng, G. J. Kelloff, V. E. Steele, M. M. Johnson, and A. M. Tari
N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells
Carcinogenesis,
May 1, 2005;
26(5):
1000 - 1007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Decensi, B. Bonanni, L. Baglietto, A. Guerrieri-Gonzaga, F. Ramazzotto, H. Johansson, C. Robertson, I. Marinucci, F. Mariette, M. T. Sandri, et al.
A Two-by-Two Factorial Trial Comparing Oral with Transdermal Estrogen Therapy and Fenretinide with Placebo on Breast Cancer Biomarkers
Clin. Cancer Res.,
July 1, 2004;
10(13):
4389 - 4397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Keedwell, Y. Zhao, L. A. Hammond, S. Qin, K.-Y. Tsang, A. Reitmair, Y. Molina, Y. Okawa, L. I. Atangan, D.-L. Shurland, et al.
A Retinoid-Related Molecule that Does Not Bind to Classical Retinoid Receptors Potently Induces Apoptosis in Human Prostate Cancer Cells through Rapid Caspase Activation
Cancer Res.,
May 1, 2004;
64(9):
3302 - 3312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Gopal, J. M. Pagel, N. Hedin, and O. W. Press
Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism
Blood,
May 1, 2004;
103(9):
3516 - 3520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Garaventa, R. Luksch, M. S. L. Piccolo, E. Cavadini, P. G. Montaldo, M. R. Pizzitola, L. Boni, M. Ponzoni, A. Decensi, B. D. Bernardi, et al.
Phase I Trial and Pharmacokinetics of Fenretinide in Children with Neuroblastoma
Clin. Cancer Res.,
June 1, 2003;
9(6):
2032 - 2039.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Formelli, T. Camerini, E. Cavadini, V. Appierto, M. G. Villani, A. Costa, G. De Palo, M. G. Di Mauro, and U. Veronesi
Fenretinide Breast Cancer Prevention Trial: Drug and Retinol Plasma Levels in Relation to Age and Disease Outcome
Cancer Epidemiol. Biomarkers Prev.,
January 1, 2003;
12(1):
34 - 41.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister
American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition
J. Clin. Oncol.,
August 1, 2002;
20(15):
3328 - 3343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Dy and A. A. Adjei
Novel Targets for Lung Cancer Therapy: Part I
J. Clin. Oncol.,
June 15, 2002;
20(12):
2881 - 2894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bruno, C. Tenca, D. Saverino, E. Ciccone, and C. E. Grossi
Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment
Carcinogenesis,
March 1, 2002;
23(3):
447 - 456.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Brown
HER-2/neu-Positive Breast Carcinoma: Molecular Concomitants by Proteomic Analysis and their Therapeutic Implications
Ann. Clin. Lab. Sci.,
January 1, 2002;
32(1):
12 - 21.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
